The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells

Cancer Immunology, Immunotherapy

Volumn 62, Issue 8, 2013, Pages 1315-1326

  Trojandt, Stefanie ^a   Knies, Diana ^a   Pektor, Stefanie ^a   Ritz, Sandra ^b   Mailänder, Volker ^b   Grabbe, Stephan ^a   Reske Kunz, Angelika B ^a   Bros, Matthias ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MAX PLANCK INSTITUTE FOR POLYMER RESEARCH   (Germany)

Author keywords

AKT; Dendritic cell; Fascin; NF B; Topotecan

Indexed keywords

GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 5; TOPOTECAN; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL CULTURE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; HEK293 CELLS; HLA-DR ANTIGENS; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULINS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; NF-KAPPA B; PHOSPHORYLATION; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84880867806     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1431-9     Document Type: Article

References (50)

1. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ (2012) DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 19:3874-3885
2. Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C (1999) Topotecan-A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56:1-12
3. Aoki D, Katsumata N, Nakanishi T, Kigawa J, Fujiwara K, Takehara K et al (2011) A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol 41:320-327
4. Suzuki H, Hirashima T, Kobayashi M, Sasada S, Okamoto N, Uehara N et al (2011) Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease. J Chemother 23:367-370
5. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721-732
6. Semenza GL (2007) Life with oxygen. Science 318:62-64
7. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47
8. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D et al (1999) Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 59:5830-5835
9. Powis G, Kirkpatrick L (2004) Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 5:647-654
10. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G (2004) Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64:1475-1482
11. Gabrilovich D (2004) Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 4:941-952
12. Wilke CM, Kryczek I, Zou W (2011) Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev Immunol 30:120-126
13. Newton K, Dixit VM (2012) Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol http://cshperspectives.cshlp.org/content/4/3/ a006049 Accessed 30 July 2012
14. Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG et al (2008) Hypoxia and hypoxia-inducible factor-1α modulate lipopolysaccharide-induced dendritic cell activation and function. J Immunol 180:4697-4705
15. Rama I, Bruene B, Torras J, Koehl R, Cruzado JM, Bestard O et al (2008) Hypoxia stimulus: an adaptive immune response during dendritic cell maturation. Kidney Int 73:816-825
16. Jonuleit H, Kühn U, Müller G, Steinbrink K, Paragnik L, Schmitt E et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135-3142
17. Bellinghausen I, Brand U, Knop J, Saloga J (2000) Comparison of allergen-stimulated dendritic cells from atopic and nonatopic donors dissecting their effect on autologous naive and memory T helper cells of such donors. J Allergy Clin Immunol 105:988-996
18. Bénard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E et al (1985) Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 45:4970-4979
19. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74
20. Fairman MP, Stillman B (1988) Cellular factors required for multiple stages of SV40 DNA replication in vitro. EMBO J 7:1211-1218
21. Sehouli J, Oskay-Ozcelik G (2009) Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin 25:639-651
22. Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, Scambia G (2010) Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 74:163-174
23. Ross R, Jonuleit H, Bros M, Ross XL, Yamashiro S, Matsumura F et al (2000) Expression of the actin-bundling protein fascin in cultured human dendritic cells correlates with dendritic morphology and cell differentiation. J Invest Dermatol 115:658-663
24. Bros M, Ross X-L, Pautz A, Reske-Kunz AB, Ross R (2003) The human fascin gene promoter is highly active in mature dendritic cells due to a stage-specific enhancer. J Immunol 171:1825-1834
25. Ross R, Ross XL, Schwing J, Längin T, Reske-Kunz AB (1998) The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. J Immunol 160:3776-3782
26. Schuette W (2001) Chemotherapy as treatment of primary and recurrent small cell lung cancer. Lung Cancer 33(Suppl 1):99-107
27. Califano R, Abidin AZ, Peck R, Faivre-Finn C, Lorigan P (2012) Management of small cell lung cancer: recent developments for optimal care. Drugs 72:471-490
28. Steinman RM, Banchereau J (2007) Taking dendritic cells into medicine. Nature 449:419-426
29. Cools N, Ponsaerts P, Van Tendeloo VFI, Berneman ZN (2007) Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 82:1365-1374
30. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT (1999) Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21:339-359
31. Curtis KK, Hartney JT, Jewell RC, Park JW, Lebowitz PF, Griffin PP et al (2010) A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer. J Clin Pharmacol 50:268-275
32. Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T et al (2011) Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian cancer study group. J Clin Oncol 29:242-248
33. Adams JC (2004) Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 16:590-596
34. Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, Rainer C et al (2002) Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol 168:4361-4371
35. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
36. Pulendran B, Tang H, Manicassamy S (2010) Programming dendritic cells to induce Th2 and tolerogenic responses. Nat Immunol 11:647-655
37. Shurin GV, Ouellette CE (2012) Shurin MR (2011) regulatory dendritic cells in the tumour immuno environment. Cancer Immunol Immunother 61(2):223-230
38. Muraille E, Leo O (1998) Revisiting the Th1/Th2 paradigm. Scand J Immunol 47:1-9
39. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192:1213-1222
40. Perkins ND (2012) The diverse and complex roles of NF-κB subunits in cancer. Nat Rev Cancer 12:121-132
41. Neumann M, Fries H-W, Scheicher C, Keikavoussi P, Kolb-Mäurer A, Bröcker E-B et al (2000) Differential expression of Rel/NF-κB and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 95:277-285
42. Scott ML, Fujita T, Liou HC, Nolan GP, Baltimore D (1993) The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms. Genes Dev 7:1266-1276
43. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA (1999) Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol 162:3865-3872
44. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C (2001) A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166:3837-3845
45. Yanagawa Y, Iijima N, Iwabuchi K, Onoé K (2002) Activation of extracellular signal-related kinase by TNF-alpha controls the maturation and function of murine dendritic cells. J Leukoc Biol 71:125-132
46. Puig-Kröger A, Relloso M, Fernández-Capetillo O, Zubiaga A, Silva A, Bernabéu C et al (2001) Extracellular signal-regulated protein kinase signalling pathway negatively regulates the phenotypic and functional maturation of monocyte-derived human dendritic cells. Blood 98:2175-2182
47. Nakahara T, Uchi H, Urabe K, Chen Q, Furue M, Moroi Y (2004) Role of c-Jun N-terminal kinase on lipopolysaccharide induced maturation of human monocyte-derived dendritic cells. Int Immunol 16:1701-1709
48. Xie J, Qian J, Yang J, Wang S, Freeman ME 3rd, Yi Q (2005) Critical roles of Raf/MEK/ERK and PI3 K/AKT signalling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 33:564-572
49. Hoarau C, Martin L, Faugaret D, Baron C, Dauba A, Aubert-Jacquin C et al (2008) Supernatant from bifidobacterium differentially modulates transduction signaling pathways for biological functions of human dendritic cells. PLoS One 3:e2753
50. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D et al (2011) Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumours. Clin Cancer Res 17:5123-5131